Commercial Partners
Worldwide network
IAD has been approved and marketed in 43 countries worldwide including EU member states (Austria, Belgium, France, Germany, Greece, Ireland, Italy, Luxemburg, Portugal and United Kingdom), Canada, Japan and Middle East territories (Bahrain, Egypt, Kuwait and U.A.E). Newport holds worldwide registrations for the trade names Isoprinosine®, Imunovir®, Viruxan®, Virimun® and Delimmun® and is the Marketing Authorisation holder in our marketing territories. IAD is marketed internationally through an expanding network of licensees and distributors.
| Country | Representative |
| Eastern Europe | Ewopharma AG |
| Egypt |
Medical Union Pharmaceutical Co. |
| Japan | Mochida Pharmaceutical Co. Ltd |
| Indonesia | PT Darya-Varia Laboratoria Tbk |
| France, Francophone Africa, Morocco, Belgium | Sanofi-Aventis |
| Italy | Sigma Tau S.p.A. |
| Greece | Uni-Pharma Kleon Tsetis S.A. |
| United Kingdom | Ardern Healthcare Ltd |
| Germany | Riemser Arzneimittel AG |
| Turkey | Gen Ilac Ltd STI |
| Malta | Cherubino Ltd |
| United Arab Emirates | Delta Medical Establishment |
| Canada | Rivex Pharma Inc |
| Kuwait | Jassim Al Wazzan General Trading |
| New Zealand | New Zealand Medical & Scientific Ltd |
Manufacturing License
NPL is licensed to batch release pharmaceuticals and investigational medicinal products into EU markets.